{
    "clinical_study": {
        "@rank": "134339", 
        "arm_group": {
            "arm_group_label": "Patients who experienced a thromboembolic event", 
            "description": "Patients who experienced a thromboembolic event during participation in the ENABLE clinical trials."
        }, 
        "brief_summary": {
            "textblock": "The objective of this observational study is to characterize long-term (5 years post event)\n      clinical outcomes in patients who experienced a thromboembolic event (TEE) during\n      participation in the GSK ENABLE clinical trials.\n\n      Patients eligible for the study are patient who experienced a TEE during participation in\n      the ENABLE trials. Each included patient will be followed for a period of 5 years from the\n      date of their first TEE. Demographic and clinical characteristics will be collected for the\n      index date (time of TEE) and every sixth month during the follow-up period, information will\n      be collected for the outcomes of interests: mortality, new TEE, hepatic decompensation,\n      evaluation for liver transplant and result of evaluation, and liver transplantation.\n\n      All information will collected by medical record review."
        }, 
        "brief_title": "Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Thromboembolism", 
                "Embolism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with portal vein thrombosis (PVT)\n\n          -  Patients with deep vein thrombosis (DVT)\n\n          -  Patients with pulmonary embolism (PE)\n\n          -  Patients with myocardial infarction (MI)\n\n          -  Patients with unstable angina\n\n          -  Patients with transient ischemic attack (TIA)\n\n          -  Patients with ischemic stroke\n\n          -  Patients with other TEE including embolism, thrombosis, phlebitis, and\n             thrombophlebitis at other locations\n\n        Exclusion Criteria:\n\n          -  There are no exclusion criteria for this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The patients under study are patients who experienced a thromboembolic event during\n        participation in the ENABLE clinical trials."
            }
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715779", 
            "org_study_id": "116951", 
            "secondary_id": [
                "WWE116951", 
                "EPI40685"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Patients who experienced a thromboembolic event", 
            "description": "Eltrombopag exposure", 
            "intervention_name": "Eltrombopag", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Liver transplantation", 
            "ENABLE", 
            "observational", 
            "mortality", 
            "Thromboembolic Events", 
            "Hepatic decompensation", 
            "Long-Term follow-up", 
            "TEE"
        ], 
        "lastchanged_date": "November 7, 2013", 
        "number_of_groups": "1", 
        "official_title": "An Observational Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: No Health Authority", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "An observational study following patients who experienced a thromboembolic event (TEE) during participation in the ENABLE trials. Each included patient will be followed for a period of 5 years from the date of their first TEE. Demographic and clinical characteristics will be collected for the index date (time of TEE) and every sixth month during the follow-up period. All information will collected by medical record review.", 
                "measure": "Mortality. Patients who experience a thromboembolic event (TEE) and died during study participation.", 
                "safety_issue": "Yes", 
                "time_frame": "The patients will be followed from 5 years from first occurrence of thromboembollic event."
            }, 
            {
                "description": "An observational study following patients who experienced a thromboembolic event (TEE) during participation in the ENABLE trials. Each included patient will be followed for a period of 5 years from the date of their first TEE. Demographic and clinical characteristics will be collected for the index date (time of TEE) and every sixth month during the follow-up period. All information will collected by medical record review.", 
                "measure": "New Thromboembolic Events (TEE). Patients who experienced a new TEE during participation.", 
                "safety_issue": "Yes", 
                "time_frame": "The patients will be followed from 5 years from first occurrence of thromboembollic event."
            }, 
            {
                "description": "An observational study following patients who experienced a thromboembolic event (TEE) during participation in the ENABLE trials. Each included patient will be followed for a period of 5 years from the date of their first TEE. Demographic and clinical characteristics will be collected for the index date (time of TEE) and every sixth month during the follow-up period. All information will collected by medical record review.", 
                "measure": "Hepatic decompensation. Patients who experienced a hepatic decompensation during study participation.", 
                "safety_issue": "Yes", 
                "time_frame": "The patients will be followed from 5 years from first occurrence of thromboembollic event."
            }, 
            {
                "description": "An observational study following patients who experienced a thromboembolic event (TEE) during participation in the ENABLE trials. Each included patient will be followed for a period of 5 years from the date of their first TEE. Demographic and clinical characteristics will be collected for the index date (time of TEE) and every sixth month during the follow-up period. All information will collected by medical record review.", 
                "measure": "Evaluation for liver transplant and result of evaluation.", 
                "safety_issue": "Yes", 
                "time_frame": "The patients will be followed from 5 years from first occurrence of thromboembollic event."
            }, 
            {
                "description": "An observational study following patients who experienced a thromboembolic event (TEE) during participation in the ENABLE trials. Each included patient will be followed for a period of 5 years from the date of their first TEE. Demographic and clinical characteristics will be collected for the index date (time of TEE) and every sixth month during the follow-up period. All information will collected by medical record review.", 
                "measure": "Liver transplantation. Patients who experienced a Liver transplantation during study participation.", 
                "safety_issue": "Yes", 
                "time_frame": "The patients will be followed from 5 years from first occurrence of thromboembollic event."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715779"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}